This December, TEDxBrisbane is bringing a suite of inspiring, uplifting talks direct to your lounge room in our first-ever virtual event.
2020 has been a challenging year for many. With so much doom and gloom in the world, it would be easy to become overwhelmed. But there’s a lot of good stuff going on too. We wanted to take a moment to celebrate that.
Our event will showcase eight custom-curated TEDx Talks, along with a selection of our favourite TED Talks, an interview with speaker Keith Chappell, co-leader of the program to develop a COVID-19 vaccine at the University of Queensland and more.
We’ve pulled together a short, punchy event for you. A three-hour block, filled with ideas worth spreading that you can watch from the comfort of your couch.
And because we think everyone deserves a little bit of inspiration this year – we’re switching from an invite-only event to a public event. If you want to tune in – we want you to join us. We’ve dramatically lowered the ticket price to make the event even more accessible in the 2020 climate, and a single ‘screen’ price (we call it a couch pass) allows you to have as many friends or family join you on your couch as current COVID restrictions in your location allow.
As we prepare to see in a new year, and a new decade, please join us as we showcase some great ideas worth spreading, that focus on finding, developing and championing solutions that will make the world good, not just better.
Associate Professor Keith Chappell is a Molecular Virologist and group leader within the University of Queensland. His research is focused on vaccine development and the understanding of medically and environmentally significant viruses. Keith is one of the inventors of UQ's molecular clamp platform and throughout 2020 he was the co-leader of the University of Queensland program to produce a vaccine for COVID-19. Keith has played a leading role in designing and implementing an epidemic response vaccine pipeline which enabled the progression of UQ's COVID-19 vaccine candidate from sequence information to clinical trial dosing within six months.